iiinova — where your digital self keeps evolving

Tim Robinson @drtimrobinson.bsky.social · 11/12/2024

And, although I’m not at SABCS this year, why do we not have data on TILS from KN522?!

Tim Robinson @drtimrobinson.bsky.social · 11/12/2024

Not at SABCS, but from afar there has to be some positive biomarkers from a trial where a significant minority don’t seem to benefit (in terms of pathCR at least) from treatment. More work needed!

000

Reposted by Tim Robinson

Trevor Graham @trevorgraham.bsky.social · 28/11/2024

We have an open #PhD #studentship as part of our "Black Leaders in Cancer" programme at @crukconvergence.bsky.social & @icrlondon.bsky.social. About computational modelling of T-cell evolution in cancer. www.findaphd.com/phds/project... I'm looking forward to meeting prospective students #CRUKfunded

findaphd.com

03328

Tim Robinson @drtimrobinson.bsky.social · 28/11/2024

I should also add that regulators have a key role here and there are signs that requirements will change. We need to using prognostic biomarkers (eg path response) and balancing the harm versus benefit of these treatments for both patients and health care systems

020

Tim Robinson @drtimrobinson.bsky.social · 28/11/2024

The SONIA trial shows the utility of well-designed academic trials. But funding such studies is getting harder and harder. We need to work with industry to design smarter trials that don’t need further costly and lengthy trials to fill gaps www.nature.com/articles/d41... @oncoalert.bsky.social #bcsm

nature.com

Toxicity and costs of cancer treatment reduced by deferring CDK4/6 inhibitor use

No difference in survival outcomes between use of CDK4/6 inhibitors as first- or second-line treatment in metastatic breast cancer.

382

Tim Robinson @drtimrobinson.bsky.social · 28/11/2024

This is potentially very interesting data but follow up is short at this point and would want to see an EFS/OS outcome. Does provide early signal and could be useful for those where steroids are contraindicated or problematic

020

Tim Robinson @drtimrobinson.bsky.social · 27/11/2024

Same comment as on the other forum!

010

Tim Robinson @drtimrobinson.bsky.social · 27/11/2024

I really like this paper and remember being impresssed when it was presented. Hats off to the authors!

010

Tim Robinson @drtimrobinson.bsky.social · 27/11/2024

It’s the best CME there is. Shame you can’t claim the time!

020

Tim Robinson @drtimrobinson.bsky.social · 26/11/2024

Certainly needs unpicking and hopefully the samples exist to do that. Did the trial contain a cytotoxic back bone? If not, I wonder if this is needed. Seemingly lots of potential but so far a complex story with anti-TIGIT molecules

000

Reposted by Tim Robinson

Jon Lim, FRCP PhD @drjonlim.bsky.social · 26/11/2024

⏰ Final call! 🧑‍🔬 Last week to apply for this fantastic opportunity to work with the exceptional @giampazolias.bsky.social at @cruk-mi.bsky.social. #TeamManchester To apply (deadline 1 Dec 2024): www.cruk.manchester.ac.uk/recruitment/...

cruk.manchester.ac.uk

Index - CrukMi.RecruitmentHr.Ui

075

Tim Robinson @drtimrobinson.bsky.social · 26/11/2024

I’m at 2 rejections for what we feel is a practice changing study. One likely ‘out of scope’, 2nd too expensive and not enough evidence of community support (multiple surveys/patient focus groups backing). Hopeful plan c being made today but it is quite exhausting!

040

Tim Robinson @drtimrobinson.bsky.social · 26/11/2024

Feel your pain. Can feel like a brick wall. But, celebrate your (very obvious) successes and remember you’re doing great and your research will make a difference!

051

Tim Robinson @drtimrobinson.bsky.social · 26/11/2024

Nice review! I’m sure we will have combination strategies in the clinic on the next few years but must balance efficacy with cost/side effect profiles

052

Tim Robinson @drtimrobinson.bsky.social · 23/11/2024

Indeed, also not without controversy I think due to AI results but more relevant than ever due to ⬆️ use. However, I’ve seen critiques of the adherence in the trial and ⬆️vaginal oestrogen doses used that are much higher than modern preparations. Always ➕/➖ when discussing with pts

020

Tim Robinson @drtimrobinson.bsky.social · 23/11/2024

Reassuring BUT short follow up at this time point

120

Tim Robinson @drtimrobinson.bsky.social · 21/11/2024

Bravo, great paper. Lots of emerging data for the PD1/TIGIT combo in the lab but data from lung trials has been disappointing. I hope that new strategies, with chemo or ADC backbones, may help circumvent this resistance. We know cytotoxics induce CSCs and it needs exploring

100

Tim Robinson @drtimrobinson.bsky.social · 21/11/2024

Interesting results, be nice to see these replicated in other eTNBC IO trials. Also to explore links with irAEs

020

Tim Robinson @drtimrobinson.bsky.social · 21/11/2024

Anecdotally, seeing an awful lot of younger patients with TNBC coming through MDT. Is anyone else seeing this?

100

Tim Robinson @drtimrobinson.bsky.social · 20/11/2024

I’m excited to see data at #SABCS but I’m also mindful that we are adding more and more to treatments and feel like we’re reaching the point that we need to start trying smarter patient selection to prevent harm @oncoalert.bsky.social #oncsky

030

Tim Robinson @drtimrobinson.bsky.social · 18/11/2024

Good list Jon, space for a trialist?

110

Tim Robinson @drtimrobinson.bsky.social · 18/11/2024

We really need some better biomarkers for immunotherapy toxicity…. Im worried we’re storing up psome big issues down the line

000

Tim Robinson @drtimrobinson.bsky.social · 14/11/2024

Yeah she’s kinda worthy of a follow!

010

Tim Robinson @drtimrobinson.bsky.social · 13/11/2024

Really important. Particularly as we are using more and more intensive treatments

020

Tim Robinson @drtimrobinson.bsky.social · 11/11/2024

Well this seems rather pleasant compared to… you know the other place

061